SCHEMBL24257971

SCHEMBL24257971

CCOC(=O)C(C(=O)OCC)c1ccc(OC)cc1C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.48
AKR1C3 P42330 5/20 0.45
AKR1C2 P52895 5/20 0.45
KDM4E B2RXH2 5/20 0.44
POLB P06746 4/20 0.44
LMNA P02545 1/20 0.44
PRNP P04156 1/20 0.44
RAB9A P51151 3/20 0.44
NPC1 O15118 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
APEX1 P27695 1/20 0.44
ALDH1A1 P00352 6/20 0.43
HPGD P15428 4/20 0.43
HSD17B10 Q99714 2/20 0.43
TSHR P16473 2/20 0.43
MAPK1 P28482 1/20 0.43
MAPT P10636 1/20 0.43
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30575774 1.00 SMN1; SMN2 (0.48) SMN1; SMN2AKR1C3AKR1C2KDM4EPOLB
SCHEMBL14915522 0.94 SMN1; SMN2 (0.46) SMN1; SMN2AKR1C3AKR1C2KDM4EPOLB
SCHEMBL22149208 0.93 SMN1; SMN2 (0.44) SMN1; SMN2AKR1C3AKR1C2KDM4EPOLB
SCHEMBL14915520 0.89 SMN1; SMN2 (0.51) SMN1; SMN2AKR1C3AKR1C2KDM4EPOLB
SCHEMBL14915840 0.83 SMN1; SMN2 (0.54) SMN1; SMN2AKR1C3AKR1C2KDM4EPOLB
SCHEMBL1044605 0.82 ALDH1A1 (0.45) KDM4EPOLBLMNARAB9ANPC1
SCHEMBL2554045 0.81 SMN1; SMN2 (0.53) SMN1; SMN2AKR1C3AKR1C2KDM4EPOLB
SCHEMBL5429818 0.81 CDC7 (0.44) AKR1C3AKR1C2KDM4ELMNAPRNP
SCHEMBL2339344 0.79 TSHR (0.49) SMN1; SMN2KDM4ELMNATDP1ALDH1A1
SCHEMBL10665110 0.79 ADRA1A (0.54) KDM4ELMNATDP1L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179087-A1 COMPOUNDS AND THEIR USES AS LPAR5 ANTAGONISTS Immunophage Biotech (Shanghai) Co., Ltd. (CN) 2025-06-05 US disclosed
US-20220048887-A1 IMPURITIES OF AMIDE-LIKE DERIVATIVES AND USE THEREOF NHWA PHARMA. CORPORATION (CN) 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048887-A1 IMPURITIES OF AMIDE-LIKE DERIVATIVES AND USE THEREOF NOTUM, CYP51A1, HADHB SMN1; SMN2 3988/4885AKR1C3 1818/4885AKR1C2 781/4885
US-20250179087-A1 COMPOUNDS AND THEIR USES AS LPAR5 ANTAGONISTS LPAR5, LPAR3, LPAR2 SMN1; SMN2 3346/4885AKR1C3 606/4885AKR1C2 588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.